These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2255 related articles for article (PubMed ID: 8050458)

  • 21. Enhanced expression of cytokines may play a fundamental role in the mechanisms of immunologically mediated recurrent spontaneous abortion.
    Shaarawy M; Nagui AR
    Acta Obstet Gynecol Scand; 1997 Mar; 76(3):205-11. PubMed ID: 9093132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes.
    Hänninen EL; Körfer A; Hadam M; Schneekloth C; Dallmann I; Menzel T; Kirchner H; Poliwoda H; Atzpodien J
    Cancer Res; 1991 Dec; 51(23 Pt 1):6312-6. PubMed ID: 1933892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The release of interleukin-8 during intravenous bolus treatment with interleukin-2.
    Baars JW; Wolbink GJ; Hart MH; Hack CE; Eerenberg-Belmer AJ; Pinedo HM; Wagstaff J
    Ann Oncol; 1994 Dec; 5(10):929-34. PubMed ID: 7696165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2.
    Kroesen BJ; Buter J; Sleijfer DT; Janssen RA; van der Graaf WT; The TH; de Leij L; Mulder NH
    Br J Cancer; 1994 Oct; 70(4):652-61. PubMed ID: 7917912
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.
    Schiller JH; Storer B; Witt PL; Nelson B; Brown RR; Horisberger M; Grossberg S; Borden EC
    Cancer Res; 1990 Aug; 50(15):4588-94. PubMed ID: 2114942
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro TNF-alpha, IL-2 and IFN-gamma production as markers of relapses in multiple sclerosis.
    Philippé J; Debruyne J; Leroux-Roels G; Willems A; Dereuck J
    Clin Neurol Neurosurg; 1996 Nov; 98(4):286-90. PubMed ID: 8930418
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced serum levels of beta-2-microglobulin, neopterin, and interferon-gamma in patients treated with recombinant tumor necrosis factor-alpha.
    Aulitzky WE; Tilg H; Herold M; Berger M; Vogel W; Judmaier G; Gastl G; Mull B; Flener R; Wiegele J
    J Interferon Res; 1988 Oct; 8(5):655-64. PubMed ID: 3148671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanoma.
    Ahmed FY; Leonard GA; A'Hern R; Taylor AE; Lorentzos A; Atkinson H; Moore J; Nicolson MC; Riches PG; Gore ME
    Br J Cancer; 1996 Oct; 74(7):1109-13. PubMed ID: 8855983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes in immunological parameters during interleukin 2 and interferon 2 alpha treatment of recurrent renal cell carcinoma and malignant melanoma.
    Maxwell W; McDevitt J; Reid I; Sharpe I; Feighery C; Tanner WA; Emmons R; Monson JR
    Eur J Surg Oncol; 1993 Jun; 19(3):265-72. PubMed ID: 8314385
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Whole body energy expenditure protein breakdown and polyamine excretion during high dose treatment with interleukin-2 and interferon-alpha.
    Naredi P; Hafström L; Zachrisson H; Rudenstam CM; Lundholm K
    Eur J Surg; 1994 Feb; 160(2):67-75. PubMed ID: 8193211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prolonged interferon-gamma application by subcutaneous infusion in cancer patients: differential response of serum CD14, neopterin, and monocyte HLA class I and II antigens.
    Landmann R; Ludwig C; Wesp M; Fisscher A; Obrist R; Knüsli C; Denz H; Obrecht JP
    J Interferon Res; 1992 Apr; 12(2):103-11. PubMed ID: 1374454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy.
    Grimm EA; Smid CM; Lee JJ; Tseng CH; Eton O; Buzaid AC
    Clin Cancer Res; 2000 Oct; 6(10):3895-903. PubMed ID: 11051235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IL-6 is a survival prognostic factor in renal cell carcinoma.
    Thiounn N; Pages F; Flam T; Tartour E; Mosseri V; Zerbib M; Beuzeboc P; Deneux L; Fridman WH; Debré B
    Immunol Lett; 1997 Jul; 58(2):121-4. PubMed ID: 9271323
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sequential interleukin-2 and alpha interferon for renal cell carcinoma and melanoma.
    Thomas H; Barton C; Saini A; Dalgleish A; Waxman J
    Eur J Cancer; 1992; 28A(6-7):1047-9. PubMed ID: 1627371
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytokine induction of neopterin production.
    Henderson DC; Sheldon J; Riches P; Hobbs JR
    Clin Exp Immunol; 1991 Mar; 83(3):479-82. PubMed ID: 1825941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neopterin release from human endothelial cells is triggered by interferon-gamma.
    Andert SE; Griesmacher A; Zuckermann A; Müller MM
    Clin Exp Immunol; 1992 Jun; 88(3):555-8. PubMed ID: 1606740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
    Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
    J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between the tumour-associated antigen 90K and cytokines in the circulation of persons infected with human immunodeficiency virus.
    Senaldi G; Peakman M; Natoli C; Hussain MJ; Gallati H; McManus T; Vergani D; Iacobelli S
    J Infect; 1994 Jan; 28(1):31-9. PubMed ID: 8163831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The in vivo immunomodulatory effects of recombinant interferon gamma plus recombinant tumor necrosis factor-alfa.
    Urba WJ; Kopp WC; Clark JW; Smith JW; Steis RG; Huber C; Coggin D; Longo DL
    J Clin Oncol; 1991 Oct; 9(10):1831-9. PubMed ID: 1919633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cellular immunity in pregnancy-induced hypertensive diseases].
    Schröcksnadel H; Herold M; Steckel-Berger G; Fuchs D; Wachter H; Dapunt O
    Geburtshilfe Frauenheilkd; 1992 Oct; 52(10):592-5. PubMed ID: 1294433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 113.